Growth and risk for islet autoimmunity and progression to type 1 diabetes in early childhood: The Environmental Determinants of Diabetes in the Young Study

Running title: Growth and risk for islet autoimmunity and diabetes

Helena Elding Larsson1*, Kendra Vehik2*, Michael J. Haller3, Xiang Liu2, Beena Akolkar4, William Hagopian5, Jeffrey Krischer2, Åke Lernmark1, Jin-Xiong She6, Olli Simell7, Jorma Toppari7,8, Anette-G. Ziegler9 and Marian Rewers10 for the TEDDY study.

* Authors contributed equally.

Members of the TEDDY Study Group are listed in Acknowledgements.

1. Department of Clinical Sciences, Lund University, Malmö, Sweden
2. Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa FL, USA
3. Department of Pediatrics, University of Florida, Gainesville, FL, USA
4. National Institute of Diabetes & Digestive & Kidney Diseases, Bethesda MD, USA
5. Pacific Northwest Diabetes Research Institute, Seattle, WA, USA
6. Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, Augusta GA, USA
7. Department of Pediatrics, Turku University Hospital, Turku, Finland
8. Departments of Physiology and Pediatrics, University of Turku, Turku, Finland
9. Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V. Neuherberg, Germany
10. Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO, USA

Corresponding author:
Helena Elding Larsson
Department of Clinical Sciences in Malmö – Pediatric Endocrinology
CRC, Jan Waldenstroms gata 35, 60:11
Skåne University Hospital
SE-205 02 Malmö
Sweden
helena.larsson@med.lu.se

Word count:
Abstract 200 words
Main text 2740 words
2 table, 2 figures
Abstract

Increased growth in early childhood has been suggested to increase the risk of type 1 diabetes. This study explored the relationship between weight, height and development of persistent islet autoimmunity and progression to type 1 diabetes during the first 4 years of life in 7,468 children at genetic risk of type 1 diabetes, followed in Finland, Germany, Sweden and US. Growth data collected every third month were used to estimate individual growth curves using mixed models. Cox proportional hazards models were used to evaluate the body size and risk of islet autoimmunity and T1D. In the overall cohort, development of islet autoimmunity (n=575) was related to weight z-scores at 12 months, (HR 1.16 per 1.14 kg in males or per 1.02 kg in females; 95%CI 1.06-1.27, p<0.001, FDR=0.008), but not at 24 or 36 months. A similar relationship was seen between weight z-scores and development of multiple islet autoantibodies (1 year, HR 1.21 95%CI 1.08-1.35, p=0.001, FDR=0.008; 2 years, HR 1.18 95% CI 1.06-1.32, p=0.004, FDR=0.02). No association was found between weight or height and type 1 diabetes (n=169). In conclusion, greater weight in the first years of life was associated with an increased risk of development of islet autoimmunity.
Introduction

Type 1 diabetes is one of the most common pediatric chronic diseases, in which a progressive autoimmune process destroys the beta-cells of pancreatic islets, resulting in loss of insulin secretion. Islet autoimmunity (IA) precedes the clinical onset of disease by months to years, and is detected by the presence of islet autoantibodies against glutamate decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and insulin (IAA)(1). An estimated 70% of children with multiple islet autoantibodies progress to diabetes within ten years (2-4). The incidence of type 1 diabetes in children has increased 3%-5% annually, since the 1960s (5; 6). The cause of this secular trend remains unknown, but it is assumed that environmental factors trigger islet autoimmunity in genetically susceptible children who carry specific Human Leucocyte Antigen (HLA) DR and DQ genotypes (7; 8). Infant overfeeding and accelerated infant/toddler growth has been proposed as a potential trigger (9). According to the ‘accelerator hypothesis’, excessive weight gain and resulting insulin resistance accelerate beta-cell apoptosis and autoimmunity in presence of the susceptibility HLA genotypes (10; 11).

While several retrospective studies have reported associations between higher birth weight (12) or childhood height and weight (13-17) and type 1 diabetes, prospective studies of IA have found less evidence for the ‘accelerator hypothesis’(18). The German BabyDiab study found no relationship between body mass index (BMI) or insulin resistance in 135 children developing IA(19); however, subsequently reported that an earlier infant BMI peak predicted IA(20). In the US DAISY study of children aged older than 2 years, an increased height velocity, but not weight or BMI velocity, predicted development of IA (n=143 children) (21). Interestingly, higher weight z-scores at age 2 and 4 years predicted development of IA (n=46) in a cohort of 548 Australian children followed from birth (22).
In this report, we tested the hypotheses that higher weight and, separately, height in the initial four years of life predict 1) the development of IA and 2) progression to type 1 diabetes. The Environmental Determinant of Diabetes in the Young (TEDDY) cohort (23) provided an opportunity to test the generalizability of evidence across four diverse populations.
Methods

Design and Settings:
TEDDY is a prospective cohort study funded by the National Institutes of Health with the primary goal of identifying environmental causes of type 1 diabetes. TEDDY includes six clinical research centers: three in the US (Colorado, Georgia/Florida, Washington) and three in Europe (Finland, Germany, and Sweden). Detailed study design and methods have been previously published (23). The study was approved by local Institutional Review Boards and is monitored by an External Evaluation Committee formed by the National Institutes of Health.

Participants:
The participants were identified at birth by screening for high-risk HLA genotypes (24). Starting in 2004, the TEDDY study included 8676 children with increased genetic risk of type 1 diabetes, who are to be followed from birth to 15 years of age. Height (length before 2 and standing height after 2 years of age) and weight of the child have been obtained at the TEDDY clinics by trained TEDDY personnel and blood samples drawn for measurements of islet autoantibodies every 3 months from 3 months up to 4 years of age and every 3-6 months after 4 years of age depending on autoantibody status. Children were excluded from these analyses (Figure 1) if: 1) their HLA eligibility could not be confirmed at a repeated genotyping at the age of 9 months; 2) their islet autoantibody results were indeterminate; 3) they had been followed for less than 12 months without developing IA or type 1 diabetes; or 4) they had more than five consecutive growth measures missing.

Main outcome measures:
Any islet autoimmunity was defined as confirmed persistent presence of one or more of islet autoantibodies on two or more sequential clinic visits. Islet autoantibodies to GAD, IA-2 and
insulin were measured by radiobinding assays (25; 26) in two reference laboratories at the Barbara Davis Center for Childhood Diabetes, University of Colorado Denver and at the University of Bristol, United Kingdom. All positive samples and 5% of negative samples were re-tested in the other reference laboratory and deemed confirmed if concordant. 

*Multiple islet autoantibodies* were defined as two or more islet autoantibodies at two consecutive clinic visits.

*Type 1 diabetes* was diagnosed using the American Diabetes Association criteria (27).

**Statistical analyses:**

The age at development of persistent confirmed IA was the age at the initial of two or more consecutive positive tests. In analyses of multiple islet autoantibodies, age of second persistent confirmed autoantibody was used. Only growth data up to the date of seroconversion to IA or to the date of diagnosis of type 1 diabetes were used. The analyses of progression to type 1 diabetes included only those children who developed persistent IA before the onset of type 1 diabetes.

Individual growth curves were developed for each child using mixed models with fixed and random effects of the height and weight on age for each gender. Best-fitting mixed models were used to produce estimates of mean growth curves and best linear unbiased predictors (BLUPS) for individual participants’ growth curves for weight and height throughout childhood. Quadratic polynomials splines were applied to model the non-linear growth curve (weight and height) from birth to four years of age. The models were examined using several potential combinations of knots from the set (0.5, 1, 1.5, 2, 3). According to Akaike Information Criteria and Bayesian Information Criterion, four knots (at 0.5, 1, 2 and 3 year respectively) were used in the fitting of weight on age and five knots (at 0.5, 1, 1.5, 2 and 3 year respectively) were used in the fitting of height on age. Standardized growth measures (weight z-score and height z-score) were derived using the CDC standardized growth
charts(28) and SAS programs. These were best represented in 0-93 months by second-degree polynomials in fixed effects and first-degree in random effects. BLUPS of individual growth curves were assessed at each time points, including those when height and weight were missing, resulting in interpolation of ~18% of the height and weight measurements. Plots of the raw data and BLUP curves were very similar. Stratified Cox proportional hazards models were used to assess specific identified periods using fixed measures (birth to 12 months, birth to 24 months and birth to 36 months) and over time using repeated measures (time-varying covariate to four years and 3, 6, 9, 12 months prior to) for association with islet autoimmunity and type 1 diabetes. All models were adjusted for presence of the HLA-DR3/4 genotype (yes/no), presence of a family history of type 1 diabetes (mother, father or sibling), gender, birth size and country of residence. There was evidence of non-proportional hazards related to country of residence in the Cox models; and, therefore the country of residence was adjusted for by using the strata statement in SAS. The strata statement allowed fitting separate baseline hazard functions for each country in the Cox models. Weight models were adjusted for birth weight z-scores and height models for birth length z-scores (28). The heterogeneity by country was tested by assessing the interaction between country and body size (weight and height z-score) in the Cox regression models. Multiple comparisons were conducted using the false discovery rate (FDR≤ 0.05 were considered significant).
Results
TEDDY children (n=8676) were followed prospectively for a median 60 months (Q1-Q3: 29-79 months). Among the 7468 children with sufficient growth data, 575 (7.7%) developed persistent IA, 351 (4.7%) multiple IA and 169 (2.3%) have progressed to type 1 diabetes (Figure 1 and Table 1). Mean age at seroconversion to persistent IA was 31 (SD=21) months, multiple IA 34 (SD=20) months and for onset of type 1 diabetes 45 (SD=23) months. A total of 109 (19%) children developed islet autoimmunity before 12 months of age, and 265 (46%) before 24 months of age. Five children (3%) progressed to type 1 diabetes before 12 month of age and 44 (26%) before 24 months of age. Table 1 summarizes demographic characteristics of the study participants. The history of type 1 diabetes in a first degree relative and the HLA-DR3/4 genotype predicted development of IA and type 1 diabetes (Table 1).

Growth parameters and development of islet autoimmunity:
In the overall cohort, there was a small increase in the risk of any persistent IA with greater toddler weight or height, adjusting for birth size, HLA-genotype, family history of type 1 diabetes, gender and country of residence, in Cox proportional hazards analysis. After correction for multiple analyses, weight z-score at 12 months (Hazard Ratio (HR) 1.16 per 1.14 kg Male/1.02 kg Female; 95%CI 1.06-1.27, p<0.001, FDR=0.008) predicted IA (Figure 2/Table 2). Using the more stringent outcome defined as positive for multiple persistent islet autoantibodies, weight z-scores at 12 and 24 months were predictive in the overall cohort, when correction for multiple analyses was performed. Hazard Ratios for any IA and multiple IA were also examined in relation to weight-z scores or height z-scores at 3, 6, 8 or 12 months prior to development of IA (Figure 2/Table 2). Little evidence was found for any excess weight or height 3-12 months prior to development of any IA or multiple IA.
In a time varying model of growth up to 4 years of age, weight z-scores were not associated with development of any IA or multiple IA (Figure 2/Suppl. Table 2). There was no evidence of heterogeneity on the effect of weight or height z-score by country on any persistent IA (all p-values ≥0.27) or multiple persistent IA (all p-values ≥0.38).

A sensitivity analysis was carried out excluding children born to mothers with type 1 diabetes; this exclusion did not affect the results. Other factors identified related to increased weight during the first year of life were, being a girl and having the HLA DR3/3, while breastfeeding for more than 3 months was associated with lower weight. However, adjustment for these factors did not change the results.

**Growth parameters and progression to type 1 diabetes:**

Growth over time did not affect time to progression to type 1 diabetes in children with multiple IA (Figure 2/Table 2). The height and weight assessed in specific intervals (birth to 12, 24 and 36 months) was also not predictive of progression from multiple islet autoantibodies to type 1 diabetes (Figure 2/Suppl. Table 2).
Discussion

In this large multi-country cohort of 7468 children at high genetic risk of type 1 diabetes we found a weak association between early weight z-scores and the development of any IA or multiple IA. The association was also found when controlling for confounding factors and correction for multiple analyses. No association between early growth and the progression to type 1 diabetes was found.

The study was performed to test the overload hypothesis, stating that increased weight could induce beta-cell autoimmunity in genetically predisposed children (9), and the accelerator hypothesis, proposing that insulin resistance due to weight gain accelerates the autoimmune process leading to type 1 diabetes (10; 11), but we could not conclusively confirm either hypothesis.

The TEDDY study is the largest prospective, longitudinal follow-up of children at risk of type 1 diabetes to date. As screening for islet autoimmunity is done every 3rd month, the time for seroconversion to IA is easy to define. At all visits height and weight are recorded, which makes it possible to evaluate growth before and after seroconversion. Therefore, TEDDY provides a unique opportunity to test the postulated overload and accelerator hypotheses. Potential confounders adjusted for or excluded using sensitivity analysis included: birth size, gender, family history of type 1 diabetes, breastfeeding and the HLA DR, DQ genotype. Further analyses may include non-HLA genetic markers that may be associated both with IA and infant/toddler growth and differ in allele frequencies between the participating countries in TEDDY.

In addition to breastfeeding, a number of infant/toddler dietary exposures have been linked to IA and type 1 diabetes (29-31). TEDDY has shown that some of the exposures vary significantly by country (32; 33). Some are also likely to increase or decrease weight gain during early childhood.
The children of this study are still young with a mean age at seroconversion to persistent IA of 31 months and at clinical onset of type 1 diabetes of 45 months. Insulin resistance as an accelerator for progression to type 1 diabetes may have a greater impact in older children (i.e., during puberty). As only a fraction of the children with IA in TEDDY have developed diabetes to date, the results may change in future analyses. The growth pattern in children with early seroconversion may also be different from the pattern of children seroconverting later in life. The TEDDY cohort will be followed to 15 years of age, which enable further analyses of growth and development of both IA and type 1 diabetes.

The TEDDY cohort was selected based on the presence of HLA genotypes with increased type 1 diabetes risk. As such, our findings may not be representative of all children developing IA and type 1 diabetes. In children with low-risk HLA genotypes, aberrations of growth may be of more significant importance for the development of type 1 diabetes, as previously described (34). It is also possible that the impact of growth on risk for type 1 diabetes may be present only in some cases and dependent of gene interactions and epigenetic factors. Since HLA genotypes associated with an increased type 1 diabetes risk are also associated with birth weight (35; 36), HLA-genotypes likely affect childhood growth. Nevertheless, increased early linear growth has been reported in children before the onset of type 1 diabetes, independent of HLA genotypes (15).

Childhood height and linear growth are strongly correlated to both maternal and paternal height (37; 38). We were not able to adjust the analyses for parental height. This may have an impact on our analyses of height data, while it would not affect weight data as much.

A number of previous studies have investigated growth in height and weight and development of type 1 diabetes, indicating that increased growth velocity may be a risk factor for type 1 diabetes (13-17). However, only few prospective investigations among children,
with the ability to separate the impact of growth on seroconversion to IA and progression to type 1 diabetes in IA positive children, have been published and results have been inconsistent. In the US DAISY study, an increased height growth velocity was associated with the risk of seroconversion (143/1714 children developed IA), while weight and BMI growth velocity had no effect (21). In the present study we could not confirm these findings. The reason for this may be that we used growth parameters from 3 months of age, while growth between 2 and 11 years of age was studied in DAISY. In an Australian study of first degree relatives to type 1 diabetes, increased weight z-score was reported as an predictor of islet autoimmunity, independent of dietary factors, in 46 children seroconverting at a low age (median 1.7 years) (22). In a study from Germany, using combined data from Babydiab and Babydiet, an early age of infant BMI peak was associated with development of IA in 135 children(20). Not being able to fully confirm those findings in our large multi-center study, we report findings similar to the Australian study. However, the weak association may indicate that growth is not the primary trigger of IA.

Insulin resistance has been suggested to accelerate the process from IA to clinically overt type 1 diabetes (39; 40). On the contrary, neither weight nor BMI velocity could be confirmed to increase the risk for progression to type 1 diabetes (n=21) in autoantibody positive children in the DAISY study, whereas height velocity independently increased the risk (21). In our current study, we were not able to study insulin resistance measured as HOMA-IR. Using weight z-score as an indicator of potential insulin resistance (41), we could not confirm previous studies indicating that insulin resistance accelerate the progression from persistent islet autoimmunity to type 1 diabetes (39; 40) (42). However, our children were young, and only in the DiME study, where HOMA-IR/FPIR predicted progression to type 1 diabetes in 77 autoantibody positive siblings of type 1 diabetes patients (42), the participants were at a comparably young age.
Greater weight in early childhood appears to predict a small increase in the risk of IA. The relevance of these findings for the future risk of diabetes will require longer follow-up of the cohort and evaluation of additional factors, such as infant feeding and genetic determinants of growth.
Acknowledgements:

Author Contributions: H.E.L. researched data and wrote manuscript, K.V. and X.L. made the statistical analyses, researched data and reviewed/edited the manuscript, M.H. researched data and reviewed/edited the manuscript, B.A., W.H., J.K., Å.L., J-X.S., O.S., J.T, A.Z. and M.R. designed the study, researched data and reviewed/edited the manuscript.

Conflict of Interest: The authors declare that there are no conflicts of interest to report regarding this study.

Guarantor statement: Helena Elding Larsson and Marian Rewers are guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The TEDDY Study Group (See online appendix)

Funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, and UC4 DK100238, and Contract No. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Juvenile Diabetes Research Foundation (JDRF), and Centers for Disease Control and Prevention (CDC). This work supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR001082).
References

10. Wilkin TJ: The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001;44:914-922
16. EURODIAB Substudy 2 Study Group: Rapid early growth is associated with increased risk of childhood type 1 diabetes in various European populations. Diabetes Care 2002;25:1755-1760
Figure legends:

Figure 1: Flow chart of the children included in The Environmental Determinants of Diabetes in the Young (TEDDY) study and the children where a full set of growth data was available for analysis. A total of 575 developed islet autoimmunity (IA), 351 multiple IA and 169 type 1 diabetes (T1D).

Figure 2: Hazard Ratios (HRs) and 95% confidence intervals for any islet autoimmunity (IA) and multiple IA (2+ IA) and T1D in relation to weight z-scores at 12, 24, and 36 months of age, change in weight z-scores 3, 6, 8 or 12 months prior to development of IA, 2+ IA and T1D and time varying growth up to 4 years of age (only events up to 4 years included). Only weight z-scores are showed since height z-scores were not significant.
Table 1. Characteristics for children developing persistent islet autoimmunity (IA) and Type 1 diabetes.

<table>
<thead>
<tr>
<th></th>
<th>Developed IA n=575</th>
<th>Did not develop IA n=6893</th>
<th>HR (95%CI)</th>
<th>Developed Type 1 diabetes n=169</th>
<th>Did not develop Type 1 diabetes n=7299</th>
<th>HR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first Ab+ visit/diagnosis of Type 1 diabetes or most recent visit (months)</td>
<td>31 (SD=21)</td>
<td>61 (SD=26)</td>
<td>45 (SD=23)</td>
<td>64 (SD=26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>25% (n=144)</td>
<td>22% (n=1513)</td>
<td></td>
<td>31% (n=52)</td>
<td>22% (n=1605)</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>8% (n=46)</td>
<td>7% (n=462)</td>
<td></td>
<td>12% (n=21)</td>
<td>7% (n=487)</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>34% (n=194)</td>
<td>30% (n=2069)</td>
<td></td>
<td>27% (n=45)</td>
<td>30% (n=2218)</td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>33% (n=191)</td>
<td>41% (n=2849)</td>
<td></td>
<td>30% (n=51)</td>
<td>41% (n=2989)</td>
<td></td>
</tr>
<tr>
<td>Family History of Type 1 diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22% (n=124)</td>
<td>10% (n=714)</td>
<td>2.36 (1.92-2.91)(^a)</td>
<td>32% (n=54)</td>
<td>11% (n=784)</td>
<td>3.70 (2.62-5.22)(^a)</td>
</tr>
<tr>
<td>High-risk HLA-DR, -DQ genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DR3/4</td>
<td>50% (n=290)</td>
<td>38% (n=2642)</td>
<td>1.71 (1.45-2.01)(^a)</td>
<td>55% (n=93)</td>
<td>39% (n=2839)</td>
<td>2.15 (1.58-2.92)(^a)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>46% (n=250)</td>
<td>49% (n=3407)</td>
<td>0.78 (0.66-0.92)(^a)</td>
<td>46% (n=77)</td>
<td>49% (n=3580)</td>
<td>0.85 (0.63-1.15)(^a)</td>
</tr>
</tbody>
</table>

Values are % (n) or mean (SD)

\(^a\)HRs adjusted for relation to type 1 proband, HLA-DR_DQ genotype, gender, age at first persistent confirmed Ab and stratified by country of residence.
Table 2. Hazard Ratios (HRs) for any islet autoimmunity (IA) and multiple IA (2+IA) and type 1 diabetes (T1D) in relation to a) weight z-scores or length/height z-scores at 12, 24, and 36 months of age, b) 3, 6, 9 and 12 months prior to IA, 2+IA or T1D, c) Time Varying Model: growth over time up to 4 years of age.

<table>
<thead>
<tr>
<th></th>
<th>Any IA</th>
<th>2+ IA</th>
<th>2+IA to T1D</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95 % CI</td>
<td>P-value</td>
</tr>
<tr>
<td><strong>Weight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) 12 mo or age</td>
<td>1.16</td>
<td>1.06-1.27</td>
<td>0.001</td>
</tr>
<tr>
<td>24 mo of age</td>
<td>1.10</td>
<td>1.01-1.20</td>
<td>0.03</td>
</tr>
<tr>
<td>36 mo of age</td>
<td>1.07</td>
<td>0.98-1.17</td>
<td>0.15</td>
</tr>
<tr>
<td>b) 12 mo of age</td>
<td>1.12</td>
<td>1.01-1.24</td>
<td>0.03</td>
</tr>
<tr>
<td>24 mo of age</td>
<td>1.07</td>
<td>0.97-1.18</td>
<td>0.20</td>
</tr>
<tr>
<td>36 mo of age</td>
<td>1.07</td>
<td>0.97-1.18</td>
<td>0.18</td>
</tr>
<tr>
<td>c) 6 mo prior</td>
<td>1.13</td>
<td>1.02-1.25</td>
<td>0.02</td>
</tr>
<tr>
<td>9 mo prior</td>
<td>1.06</td>
<td>0.95-1.18</td>
<td>0.29</td>
</tr>
<tr>
<td>12 mo prior</td>
<td>1.08</td>
<td>0.97-1.21</td>
<td>0.16</td>
</tr>
<tr>
<td>3 mo prior</td>
<td>1.12</td>
<td>0.99-1.26</td>
<td>0.06</td>
</tr>
<tr>
<td>6 mo prior</td>
<td>1.03</td>
<td>0.92-1.15</td>
<td>0.66</td>
</tr>
<tr>
<td>9 mo prior</td>
<td>1.06</td>
<td>0.95-1.19</td>
<td>0.32</td>
</tr>
<tr>
<td>12 mo prior</td>
<td>0.98</td>
<td>0.87-1.11</td>
<td>0.80</td>
</tr>
<tr>
<td>Length/Height</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) 12 mo of age</td>
<td>1.07</td>
<td>0.94-1.22</td>
<td>0.32</td>
</tr>
<tr>
<td>24 mo of age</td>
<td>1.11</td>
<td>1.01-1.23</td>
<td>0.04</td>
</tr>
<tr>
<td>36 mo of age</td>
<td>1.08</td>
<td>0.97-1.21</td>
<td>0.17</td>
</tr>
</tbody>
</table>

HRs adjusted for birth weight z-score (for weight z-score models) and birth length z-scores (for length/height z-score models), relation to type 1 proband, HLA-DR_DQ genotype and gender, and stratified by country of residence.

*FDR = False Discovery Rate
Enrolled TEDDY population
n=8676

Exclusions (n=1208):
1. HLA ineligible (n=116)
2. Indeterminate autoantibodies (n=57)
3. Follow-up less than 12 months (n=1035)
4. More than five consecutive growth measurements missing

Eligible population for growth analyses
n=7468

IA n=575 (≥2 1A n=351)
Type 1 diabetes n=169

No IA n=6893
No type 1 diabetes n=7299
Figure 2
232x119mm (300 x 300 DPI)
Appendix

The Teddy Study Group

**Colorado Clinical Center:** Marian Rewers, M.D., Ph.D., PI²,⁴,⁵,⁶,¹⁰,¹¹, Kimberly Bautista¹, Judith Baxter⁷,⁸,⁹,¹⁰,¹²,¹⁵, Ruth Bedoy⁴, Daniel Felipe-Morales, Brigitte Frohnert, M.D., Patricia Gesualdo²,⁶,¹²,¹₄,¹⁵, Michelle Hoffman¹₂,¹₃,¹⁴, Rachel Karban¹₂, Edwin Liu, M.D.¹₃, Jill Norris, Ph.D.²,³,¹₂, Adela Samper-Imaz, Andrea Steck, M.D.³,¹₄, Kathleen Waugh⁶,⁷,¹₂,¹₅, Hali Wright¹₂. University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

**Georgia/Florida Clinical Center:** JinEXiong She, Ph.D., PI¹,³,⁴,¹¹, Desmond Schatz, M.D.*⁴,⁵,⁷,⁸, Diane Schatz, M.D.*⁴,⁵,⁷,⁸, Diane Hopkins¹₂, Leigh Steed¹₂,¹₃,¹₄,¹₅, Jamie Thomas*, Katherine Silvis², Michael Haller, M.D.*¹⁴, Meena Shankar*, Eleni Sheehan*, Melissa Gardiner, Richard McIndoe, Ph.D., Ashok Sharma, Joshua Williams, Gabriela Foghis, Stephen W. Anderson, M.D.*^, Richard Robinson. Center for Biotechnology and Genomic Medicine, Georgia Regents University. *University of Florida, Pediatric Endocrine Associates, Atlanta.

**Germany Clinical Center:** Anette G. Ziegler, M.D., PI¹,³,⁴,¹¹, Andreas Beyerlein Ph.D.², Ezio Bonifacio Ph.D.*³, Michael Hummel, M.D.¹³, Sandra Hummel, Ph.D.², Kristina Foterek¹², Mathilde Kersting, Ph.D.¹², Annette Knopff⁷, Sibylle Koletzko, M.D.¹³, Claudia Peplow¹₂, Roswith Roth, Ph.D.⁹, Joanna Stock⁹,¹₂, Elisabeth Strauss¹₂, Katharina Warncke, M.D.¹₄, Christiane Winkler, Ph.D.²,¹₂,¹₅. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München. *Center for Regenerative Therapies, TU Dresden, †Dr. von Hauner Children’s Hospital, Department of Gastroenterology, Ludwig Maximillians University Munich, ¶Research Institute for Child Nutrition, Dortmund.

**Finland Clinical Center:** Jorma Toppari, M.D., Ph.D., PI¹,³,⁴,¹₁,¹₄, Olli G. Simell, M.D., Ph.D.*¹,³,⁴,¹₁,¹₃, Annika Adamsson, Ph.D.*¹², Heikki Hyöty, M.D., Ph.D.*¹⁶, Jorma Ilonen, M.D., Ph.D.*¹³, Jorma Ilonen, M.D., Ph.D.*¹³, Sanna Jokipuu¹³, Tiina Kailiarii¹³, Mika Kähönen¹³, Mikael Knip, M.D., Ph.D.*¹₃, Annika Koivu¹³, Mirva Kerosalo*¹², Kalle Kurppa, M.D., Ph.D.*¹³, Maria Lönnrot, M.D., Ph.D.*¹₆, Elina Mäntymäki¹³, Katja Multasuo¹³, Juha Mykkänen, Ph.D.*¹³, Tiina Niininen*¹², Mia Nyblom*, Petra Rajala¹³, Jenna Rautanen¹⁳, Anne Riikonen¹³, Minna Romo¹³, Satu Simell, M.D., Ph.D.*¹³, Tuula Simell, Ph.D., Ville Simell¹³, Maija Sjöberg*¹₂,¹₄, Aino Stenius¹³, Maria Särmä¹³, Sini Vainionpää¹³, Eeva Varjonen¹₂, Riitta Viejola, M.D., Ph.D.*¹², Suvi M. Virtanen, M.D., Ph.D.*¹², Mari Vähä-Mäkilä¹³, Mari Åkerlund*¹₆, *University of Turku, *University of Tampere, ¶University of Oulu, "Turku University Hospital, Hospital District of Southwest Finland, "Tampere University Hospital, "Oulu University Hospital, §National Institute for Health and Welfare, Finland, ¶University of Kuopio.

**Sweden Clinical Center:** Åke Lernmark, Ph.D., PI¹,³,⁴,⁵,⁶,⁸,¹₀,¹₁,¹₅, Daniel Agardh, M.D., Ph.D.*¹³, Carin Andrén Aronsson¹³, Maria Ask, Jenny Bremer, Ulla-Marie Carlsson, Corrado Cilio, Ph.D., M.D.³, Emelie Ericson-Hallström, Linda Fransson, Thomas Gard, Joanna Gerardsson, Rasmus Bennet, Monica Hansen, Gertie Hansson¹₃, Susanne Hyberg, Fredrik Johansen, Berglid Jonsdottir M.D., Linda Jonsson, Helena Elding Larsson M.D., Ph.D.²,¹₄, Sigrid Lenrick Forss, Maria Månsdotter-Martinez, Maria Markan, Jessica Melin¹³, Zeliha Mestan, Kobra Rahmati, Anita Ramelius, Anna Rosenquist, Falastin Salami, Sara Sibthorpe, Birgitta
Sjöberg, Ulrica Swartling, Ph.D. [9,12], Evelyn Tekum Amboh, Erika Trulsson, Carina Törn, Ph.D. [3,15], Anne Wallin, Åsa Wimar [12,14], Sofie Åberg. Lund University.

Washington Clinical Center: William A. Hagopian, M.D., Ph.D., PI [1,3,4, 5, 6,7,11,13,14], Xiang Yan, M.D., Michael Killian [6,7,12,13], Claire Cowen Crouch [12,14,15], Jennifer Skidmore [2], Stephen Ayres, Kayleen Dunson, Diana Heaney, Rachel Hervey, Corbin Johnson, Rachel Lyons, Arlene Meyer, Denise Mulenga, Emma Schulte, Elizabeth Scott, Joshua Stabbert, John Willis. Pacific Northwest Diabetes Research Institute.

Pennsylvania Satellite Center: Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith [2], Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children’s Hospital of Pittsburgh of UPMC.

Data Coordinating Center: Jeffrey P. Krischer, Ph.D., PI [1,4,5,10,11], Michael Abbondondolo, Sarah Austin-Gonzalez, Sandra Baethke, Rasheedah Brown [12,15], Brant Burkhardt, Ph.D. [5,6], Martha Butterworth [2], Joanna Clasen, David Cuthbertson, Christopher Eberhard, Steven Fiske [9], Dena Garcia, Jennifer Garmes, Veena Gowda, David Hadley, Ph.D., Kathleen Heyman, Hye-Seung Lee, Ph.D. [1,2,13,14], Shu Liu, Xiang Liu, Ph.D. [2,3,9,14], Kristian Lynch, Ph.D. [5,6,9,15], Jamie Malloy, Cristina McCarthy [12,15], Wendy McLeod, Steven Meulemans, Chris Shaffer, Laura Smith, Ph.D. [3,9,12], Susan Smith [12,15], Roy Tamura, Ph.D. [1,2,13], Ulla Uusitalo, Ph.D. [2,15], Kendra Vehik, Ph.D. [4,5,6,14,15], Ponni Vijayakandipan, Keith Wood, Jimin Yang, Ph.D., R.D. [2,15]. University of South Florida.

Project scientist: Beena Akolkar, Ph.D. [1,3,4,5, 6,7,10,11]. National Institutes of Diabetes and Digestive and Kidney Diseases.

Other contributors: Kasia Bourcier, Ph.D. [5], National Institutes of Allergy and Infectious Diseases. Thomas Briese, Ph.D. [6,15], Columbia University. Suzanne Bennett Johnson, Ph.D. [9,12], Florida State University. Steve Oberste, Ph.D. [6], Centers for Disease Control and Prevention. Eric Triplett, Ph.D. [6], University of Florida.

Autoantibody Reference Laboratories: Liping Yu, M.D. [5], Dongmei Miao, M.D. [6], Polly Bingley, M.D., FRCP [5], Alistair Williams*, Kyla Chandler*, Saba Rokni*, Claire Caygill*, Nicholas Lovis, Claire Williams, Rebecca Wyatt*. *Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, *School of Clinical Sciences, University of Bristol UK.

Cortisol Laboratory: Elisabeth Aardal Eriksson, M.D., Ph.D., Ing-Marie Lundgren, Ewa Lönn Karlsson, Dzeneta Nezirevic Dernroth, Ph.D. Department of Clinical Chemistry, Linköping University Hospital, Linköping, Sweden.


HbA1c Laboratory: Randie R. Little, Ph.D., Alethea L. Tennill. Diabetes Diagnostic Laboratory, Dept. of Pathology, University of Missouri School of Medicine.

HLA Reference Laboratory: Henry Erlich, Ph.D. [3], Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children’s Hospital Oakland Research Institute.

Metabolomics Laboratory: Oliver Fiehn, Ph.D., Bill Wikoff, Ph.D., Brian Defelice, Dmitry Grapov, Ph.D., Tobias Kind, Ph.D., Mine Palazoglu, Luis
Valdiviez, Benjamin Wancewicz, Gert Wohlgemuth, Joyce Wong. UC Davis Metabolomics Center.

**Microbiome and Viral Metagenomics Laboratory:** Joseph F. Petrosino, Ph.D. Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine.

**OGTT Laboratory:** Santica M. Marcovina, Ph.D., Sc.D., Vinod P. Gaur, Ph.D., Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington.

**Proteomics Laboratory:** Richard D. Smith, Ph.D., Thomas O. Metz, Ph.D., Charles Ansong, Ph.D., Bobbie-Jo Webb-Robertson, Ph.D., and Hugh D. Mitchell, Ph.D. Pacific Northwest National Laboratory.

**Repository:** Heather Higgins, Sandra Ke. NIDDK Biosample Repository at Fisher BioServices.

**RNA Laboratory and Gene Expression Laboratory:** Jin-Xiong She, Ph.D., PI1,3,4,11, Richard McIndoe, Ph.D., Haitao Liu, M.D., John Nechtman, Yansheng Zhao, Na Jiang, M.D., Yanna Tian, M.S. Guangkuo Dong, M.S. Jinfiniti Biosciences, LLC.

**SNP Laboratory:** Stephen S. Rich, Ph.D.3, Wei-Min Chen, Ph.D.3, Suna Onengut-Gumuscu, Ph.D.3, Emily Farber, Rebecca Roche Pickin, Ph.D., Jordan Davis, Dan Gallo, Jessica Bonnie, Paul Campolieto. Center for Public Health Genomics, University of Virginia.

**Committees:**
1Ancillary Studies, 2Diet, 3Genetics, 4Human Subjects/Publicity/Publications, 5Immune Markers, 6Infectious Agents, 7Laboratory Implementation, 8Maternal Studies, 9Psychosocial, 10Quality Assurance, 11Steering, 12Study Coordinators, 13Celiac Disease, 14Clinical Implementation, 15Quality Assurance Subcommittee on Data Quality.